

### Patent Claims

1. Stable formulation of a solution consisting of  
xylometazoline hydrochloride and oxymetazoline  
5 hydrochloride as active substance, a solvent which is  
pharmacologically acceptable for nasal  
administration, an adjuvant selected from among  
sorbitol and/or glycerol and an inorganic pH buffer.
- 10 2. Formulation according to claim 1, characterised in  
that the active substance is present in a  
concentration of between 0.01 and 1.0% by weight,  
preferably between 0.01 and 0.5% by weight and most  
preferably between 0.05 and 0.1% by weight.
- 15 3. Formulation according to one of claims 1 and 2,  
characterised in that the solvent is water.
4. Formulation according to one of claims 1 and 2,  
20 characterised in that the solvent is a mixture of  
ethanol and water.
5. Formulation according to one of claims 1 to 4,  
characterised in that the proportion of adjuvant in  
25 the solution is 1 to 10% by weight, preferably 2 to  
6% by weight.
6. Formulation according to claim 5, characterised in  
that the adjuvant is 3.5 to 4.5% by weight,  
30 preferably 4.0% by weight, of sorbitol.
7. Formulation according to claim 6, characterised in  
that the adjuvant is 2.0 to 2.8% by weight,  
preferably 2.4% by weight, of glycerol.

8. Formulation according to one of claims 1 to 7,  
characterised in that the solution contains a sodium  
and/or potassium phosphate buffer or a sodium and/or  
potassium borate buffer.
- 5
9. Formulation according to one of claims 1 to 8,  
characterised in that the solution contains a  
monosodium dihydrogen-disodium monohydrogen phosphate  
buffer and/or monopotassium dihydrogen-dipotassium  
monohydrogen phosphate buffer.
- 10
10. Formulation according to one of claims 1 to 9,  
characterised in that the solution is adjusted to a  
pH of 5.0 to 6.8, preferably 5.5 to 6.8, most  
preferably 5.8 to 6.0.
- 15
11. Formulation according to one of claims 1 to 10,  
characterised in that the formulation contains an  
oligodynamically active substance.
- 20
12. Formulation according to claim 11, characterised in  
that the oligodynamic substance is silver or silver  
ions..
- 25
13. Formulation according to one of claims 1 to 12,  
characterised in that the formulation contains only  
xylometazoline hydrochloride as active substance.
- 30
14. Formulation according to one of claims 1 to 12,  
characterised in that the formulation contains only  
oxymetazoline hydrochloride as active substance.
- 35
15. Use of a formulation according to claims 1 to 14  
together with an inhaler having silver-containing  
elements in the region between the active substance  
reservoir and the sprayhead.

16. Use of the formulation according to one of claims 1 to 13 as a rhinological agent.